RTOG® RADIATION THERAPY ONCOLOGY GROUP

ASTRO 2011 Annual Meeting Presentations (Listed by Disease Site)

RTOG Study #	Presentation Title & Authors	Session	Presentation Date & Time
Bladder Cancer			
Multiple (8802, 8903, 9506, 9706)	**Bladder Preservation Therapy for Muscle-Invading Bladder Cancers (MIBC): Long-term Clinical Outcomes from RTOG 8802, 8903, 9506, and 9706 and Molecular Correlates Along the VEGF Pathway** *Chakravarti A, James JL, Efstathiou JA, Wu CL, Klimowicz A, Sandler H, Lautenschlaeger T, Tester WJ, Hagan MP, Shipley WU*	Scientific Session C: GU I- Prognostic Factors and Prostate Brachytherapy	Monday, October 3, 2011 10:45 a.m. - 12:15 p.m. Junior Ballroom A
Brain Tumors			
RTOG 0513	**Phase I/II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60 GY Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma (GBM): Results of RTOG 0513** *Brachman DG, Wang M, Ashby LS, Thomas TA, Dunbar E, Rockhill JK, Khuntia D, Bovi JA, Macher MS, Mehta MP*	Scientific Session EE: Central Nervous System	Wednesday, October 5, 2011 1:30 p.m. - 3:00 p.m. Rm B118
RTOG 0525	**RTOG 0525: Exploratory Subset Analysis From a Randomized Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) With a Dose-Dense (dd) Schedule for Glioblastoma (GBM).** *Mehta M, Wang M, Aldape K, Stupp R, Jaeckle KA, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Curran WJ, Gilbert MR*	Scientific Session EE: Central Nervous System	Wednesday, October 5, 2011 1:30 p.m. - 3:00 p.m. Rm B118
RTOG 0611	**Predictive Value of Tumor Recurrence Using Urinary VEGF Levels in Patients Receiving Radiation Therapy for Glioblastoma** *Camphausen K, Wang M, Corn BW, Muanza TM, Howard SP, Mahadevan A, Schultz CJ, Haas ML, Mehta MP*	Digital Poster Discussion 05: Central Nervous System	Tuesday, October 4, 2011 2:45 p.m. - 4:15 p.m Junior Ballroom C
Breast Cancer			
RTOG 0413	**Early Toxicity Results with 3-D Conformal External Beam Therapy (CEBT) from the NSABP B-39/RTOG 0413 Accelerated Partial Breast Irradiation (APBI) Trial** *Julian TB, Costantino JP, Vicini FA,White JR, Arthur DW, Kuske RR, Rabinovitch R, Winter KA, Curran WJ, Wolmark N*	Scientific Session B: Breast: Partial Breast Irradiation and Hypofractionated Radiation	Monday, October 3, 2011 10:45 a.m. - 12:15 p.m. Rm B214
Gastrointestinal Cancer			
RTOG 0012	**5-Year Updated Results of RTOG-0012 Randomized Phase II Study of Neoadjuvant Combined Modality Chemoradiation for Distal Rectal Cancer.** *Mohiuddin M, Winter K, Mitchell EP, Hanna NN, Yuen A, Nichols RC, Yalavartihi S, Hayostek CJ, Willett C,*	Scientific Session W: GI II- Neoadjuvant Treatment of Rectal Cancer	Wednesday, October 5, 2011 10:45 a.m. - 12:15 p.m. Junior Ballroom A

RTOG 0247	**Longitudinal Quality of Life (QoL) and Patient-Reported Bowel Function in RTOG 0247: A Randomized Phase II Study of Neoadjuvant Capecitabine and Irinotecan or Capecitabine and Oxaliplatin with Concurrent Radiation Therapy for Locally Advanced Rectal Cance** *Kachnic L, Winter K, Meropol NJ, Anne PR, Wong SJ, Watson JC, Mitchell EP, Pollock J, Lee RJ, Willett CG*	Scientific Session W: GI II- Neoadjuvant Treatment of Rectal Cancer	Wednesday, October 5, 2011 10:45 a.m. - 12:15 p.m. Junior Ballroom A
RTOG 0822	**RTOG 0822: A Phase II Evaluation of Preoperative Chemoradiotherapy (CRT) Utilizing IMRT in Combination With Capecitabine (C) and Oxaliplatin (O) for Patients With Locally Advanced Rectal Cancer** *Garofalo MC, Moughan J, Hong TS, Bendell J, Berger AC, Lerma F, Lee RJ Anne PR, Sharma NK, Crane CH*	Scientific Session A: Clinical Trials	Monday, October 3, 2011 10:45 a.m. - 12:15 p.m. Hall B
RTOG 9811	**Long-term Update of U.S. GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Disease-free and Overall Survival With 5FU-Mitomycin vs 5FU-Cisplatin** *Gunderson LL, Moughan J, Ajani JA, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG*	Scientific Session A: Clinical Trials	Monday, October 3, 2011 10:45 a.m. - 12:15 p.m. Hall B
Gynecologic Cancer			
RTOG 0418	**Efficacy And Safety of IMRT After Surgery in Patients With Endometrial Cancer: RTOG 0418 Phase II Study** *Jhingran A, Winter K, Portelance L, Miller BE, Salehpour MR, Gaur R, Souhami L, Small W, Gaffney D.*	Scientific Session K: GYN	Tuesday, October 4, 2011 11:45 a.m. - 1:15 p.m. Rm B118
RTOG 0418	**A Phase II Multi-Institutional Study of Postoperative Pelvic IMRT With Weekly Cisplatin in Patient With Cervical Carcinoma: Two Year Efficacy Results of the RTOG 0418** *Portelance L, Moughan J, Jhingran A, Miller BE, Salehpour MR, D'Souza D, Haddock M, Rotman M, Gaffney D.*	Scientific Session A: Clinical Trials	Monday, October 3, 2011 10:45 a.m. - 12:15 p.m. Hall B
Head and Neck Cancer			
RTOG 0129	**Predictors on Longitudinal Changes of Symptom Clusters Identified in Patients With Head and Neck Cancer Treated on RTOG Trials** *Xiao C, Hanlon A, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Kim H, Movsas B, Watkins-Bruner D*	Poster Viewing Session	October 2-4, 2011 10:00 a.m. - 5:00 p.m. Hall A (ASTRO abs# 2675)
Lung Cancer			
RTOG 0235	**Can FDG-PET Standardized Uptake Value (SUV) findings predict Local Control in Stage III NSCLC?: Preliminary Results from ACRIN 6668/RTOG 0235** *Machtay M, Duan F, Snyder B, Gorelick J, DeNittis A, Chiles C, Mahon I, Alavi A, Siegel B, Bradley J*	Scientific Session FF: Lung III- Clinical Trials/Outcomes	Wednesday, October 5, 2011 1:30 p.m. - 3:00 p.m. Ballroom A
RTOG 0236	**Dosimetric Verification Using Monte Carlo Calculations for Tissue Heterogeneity-corrected Conformal Treatment Plans for Lung Cancer Stereotactic Body Radiotherapy** *Li J, Galvin JM, Harrison A, Timmerman R, Yu Y, Xiao Y*	Poster Viewing Session	October 2-4, 2011 10:00 a.m. - 5:00 p.m. Hall A (ASTRO abs# 3349)

RTOG 0617	**A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-dose (74 Gy) Conformal Chemoradiotherapy +/- Cetuximab for Stage IIIA/IIIB Non-Small Cell Lung Cancer: Preliminary Findings on Radiation Dose in RTOG 0617** *Bradley JD, Paulus R, Komaki R, Masters G, Forster K, Schild S, Bogart JA, Garces YI, Narayan S, Choy H*	Plenary session (LB)	Monday, October 3, 2011 2:15 p.m. - 3:30 p.m Hall B - General Session .
RTOG 1106	**Establishment of a Pre-Clinical Trial Process for Dosimetric Feasibility Study of Adaptive Radiotherapy for Patients with Stage III NSCLC** *Xiao Y, Cui Y, Kong FM, Appenzoller L, Beatty R, Maxim P, Ritter T, Sohn J, Higgins J, Galvin J*	Poster Viewing Session	October 2-4, 2011 10:00 a.m. - 5:00 p.m. Hall A (ASTRO abs# 2840)
RTOG 1106	**Using During-RT PET to Individualize Adaptive RT for Patients With Stage III NSCLC: A RTOG Planning Study** *Kong FM, Machtay M, Videtic G, Loo BW, Gore E, Wagner H, Varlotto J, Faria S, Dilling T, Sun A*	Poster Viewing Session	October 2-4, 2011 10:00 a.m. - 5:00 p.m. Hall A (ASTRO abs# 2818)
Multiple (0212, 0124)	**Decline in tested and patient-reported cognitive functioning following prophylactic cranial irradiation for lung cancer: Secondary analysis of RTOG 0212 and 0214** *Gondi V, Paulus R, Bruner DW, Meyers CA, Gore EM, Wolfson A, Werner-Wasik M, Choy H, Movsas B*	Scientific Session L: Lung I- Toxicity/PET	Tuesday, October 4, 2011 11:45 a.m. - 1:15 p.m. Rm A201
Multiple	**Process and Initial Experience of Remote Credentialing of 3D IGRT Data for Institutions Participating in RTOG Clinical Trials** *Cui Y, Galvin JM, Parker W, Breen S, Yin FF, Papiez L, Li AX, Bednarz G, Chen W, Xiao Y*	Poster Viewing Session	October 2-4, 2011 10:00 a.m. - 5:00 p.m. Hall A (ASTRO abs# 3257)
Prostate Cancer			
RTOG 0126	**Preliminary Analysis of RTOG 0126 High Dose Arm Prostate Patients Receiving 3DCRT or IMRT: Patient Reported Outcomes** *Bruner DW, Hunt D, Michalski JM, Bosch W, Yan Y, Galvin JM, Bahary JP, Morton GC, Parliament MB, Sandler H*	Scientific Session J: GU II- Seminoma and Prostate Cancer: EBRT, Androgen Deprivation and Their Toxicities	Tuesday, October 4, 2011 11:45 a.m. - 1:15 p.m. Junior Ballroom A
RTOG 0126	**Preliminary Analysis of RTOG 0126 High Dose Arm Prostate Patients Receiving 3DCRT or IMRT: Toxicity Report** *Michalski JM, Yan Y, Bruner DW, Bosch W, Winter K, Galvin JM, Bahary JP, Morton GC, Parliament MB, Sandler H*	Plenary session (2)	Monday, October 3, 2011 2:15 p.m. - 3:30 p.m. Hall B - General Session
RTOG 0232	**Analysis of Brachytherapy Plans for Regulatory Compliance: Dosimetric Study of RTOG 0232 Plans to Quantify Expected Dose to Organs at Risk** *Bosch W, Paulus R, Michalski JM, Galvin JM, Followill DS, Bice WS, Prestidge BR, Sandler H, Hagan M*	Poster Viewing Session	October 2-4, 2011 10:00 a.m. - 5:00 p.m. Hall A (ASTRO abs# 2354)
RTOG 0321	**Dosimetric Parameters of Prostate HDR Brachytherapy in Radiation Therapy Oncology Group 0321** *Hsu I, Hunt D, Pouliot J, Speight JL, Vigneault E, Ivker R, Sandler H.*	Scientific Session C: GU I- Prognostic Factors and Prostate Brachytherapy	Monday, October 3, 2011 10:45 a.m. - 12:15 p.m. Junior Ballroom A
RTOG 0828	**Electronic Web-Based Technology Significantly Improves Quality of Life (QOL) Data Collection: Analysis of RTOG 0828** *Movsas B, Hunt D, Bruner DW, Lee WR, Tharpe H, Goldstein D, Shah AB, Dayes IS, Parise S, Sandler H*	Scientific Session Z: Palliative/Quality of Life	Wednesday, October 5, 2011 10:45 a.m. - 12:15 p.m. Rm A107

RTOG 9408	**Ki-67 Staining Is a Strong Predictor of Patient Outcome for Prostate Cancer Patients Treated on RTOG 94-08** *Ritter MA, Yan Y, Verhoven B, Khor L-Y, Hammond ME, Jones CU, Amin MB, Bahary JP, Zeitzer KL, Pollock A*	Scientific Session C: GU I- Prognostic Factors and Prostate Brachytherapy	Monday, October 3, 2011 10:45 a.m. - 12:15 p.m. Junior Ballroom A
RTOG 9408	**Cardiovascular Mortality Following Short-Term Androgen Deprivation In Clinically Localized Prostate Cancer: An Analysis Of RTOG 94-08** *Efstathiou JA, Paulus R, Smith MR, Jones CU, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU,*	Scientific Session J: GU II- Seminoma and Prostate Cancer: EBRT, Androgen Deprivation and Their Toxicities	Tuesday, October 4, 2011 11:45 a.m. - 1:15 p.m. Junior Ballroom A
Multiple (9202, 9413)	**Surrogate End-Points for Prostate Cancer Specific Survival: Superiority of the Interval to Biochemical Failure: An Analysis of RTOG 9202 and 9413** *Hamstra DA, Dignam J, Porter A, Hanks GE, Lawton C, Roach M, Sandler H.*	Scientific Session X: GU IV- Prostate Cancer: Hypofractionation and Health Policy	Wednesday, October 5, 2011 10:45 a.m. - 12:15 p.m. Rm B214
N/A companion study	**Analysis of Brachytherapy Plans for Regulatory Compliance: Application of Expected Doses to Organs at Risk** *Hagan M, Bosch W, Moore M, Prestidge B, Bice W, Paulus R, Galvin J, Sandler H, Winter K, Michalski J*	Poster Viewing Session	October 2-4, 2011 10:00 a.m. - 5:00 p.m. Hall A (ASTRO abs# 2370)
Sarcoma			
RTOG 0630	**A RTOG Phase II Trial of Image Guided Preoperative Radiotherapy For Primary Soft Tissue Sarcoma of the Extremity: Acute Toxicity Report** *Wang D, Zhang Q, Kirsch DG, Okuno SH, , Kane JM, Li XA, Roberge D, Finkelstein S, DeLaney T ,Eisenberg BL*	Scientific Session BB: Sarcoma	Wednesday, October 5, 2011 10:45 a.m. - 12:15 p.m. Rm B113
RTOG CAMAS Atlas	**Deformable Imaging Capability for the Radiation Therapy Oncology Group (RTOG) Consensus Atlas of Musculoskeletal Anatomy (CAMAS) for Soft Tissue Sarcoma of the Lower Extremities** *Finkelstein SE, Trotti A, Letson GD, Russel M, DeLaney TF, Alektair KM, Michalski J, Wang D, Kadir T, Stevens C*	Poster Viewing Session	October 2-4, 2011 10:00 a.m. - 5:00 p.m. Hall A (ASTRO abs# 2992)
Symptom Management & Bone Metastases			
RTOG 0631	**RTOG 0631 Phase II/III Study of Image-Guided Stereotactic Radiosurgery for Localized Spine Metastases: Phase II Results** *Ryu S, James JL, Gerszten P, Yin FF, Timmerman RD, Hitchcock Y, Movsas B, Kanner AA, Berk LB, Kachnic LA*	Scientific Session EE: Central Nervous System	Wednesday, October 5, 2011 1:30 p.m. - 3:00 p.m. Rm B118